Market Overview

UPDATE: Morgan Stanley Reiterates on AbbVie After Competitor's Schizophrenia Drug Fails

Share:
Related
Benzinga's M&A Chatter for Wednesday August 19, 2015
Jim Cramer Advises His Viewers On Halozyme Therapeutics, CF Industries And Tower International
On Babies And Bathwater (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on AbbVie (NYSE: ABBV), but removed the $57.00 price target.

In the report, Morgan Stanley noted, “Targacept's (not covered) cognitive deficits in schizophrenia (CDS) drug, TC-5619, failed. This drug is similar to ABBV's ABT-126, which is being tested in Ph. IIb in both cognition in Alzheimer's and CDS. We have been estimating 20% odds of ABBV success in one of the two indications.”

AbbVie closed on Monday at $53.37.

Latest Ratings for ABBV

DateFirmActionFromTo
Jul 2015Deutsche BankMaintainsBuy
Jul 2015SunTrust Robinson HumphreyInitiates Coverage onBuy
Jun 2015Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!

Get Benzinga's Newsletters